Immunosequencing
The Innovation Behind Innovation
About ImmunoSequencing
immunoSEQ® Platform Technology
An overview of the immunoSEQ Assay technology describing the PCR amplification bias control and high throughput sequencing used to identify millions of T- and B-cell receptors in a single sample.
HOW IT WORKS
immunoSEQ Assays give researchers a high-definition view of the adaptive immune system. It’s now possible to explore broad characteristics of T-and B-cell repertoires as well as the unique details of individual clones. Whether you are investigating the general trends of the immune system or specific clones, you can be confident in your data with the quantitative1 and reproducible2 results of immunoSEQ Assays behind your research.
Receptor Profiling
QUANTIFIABLE RESULTS
Employing highly optimized PCR primers and a synthetic immune repertoire with computational algorithms, the immunoSEQ Assay delivers accurate, quantifiable results.1
May be covered by one or more of US Patent Nos. 9,150,503; 9,371,582; 9,809,813; 9,394,567; 8,883,418, and foreign equivalents
Primer concentrations adjusted to significantly reduce PCR amplification bias
+
Built-in controls assessed with every sample for true quantification
+
Corrects residual PCR amplification bias and quantifies T-cell or B-cell clones
VIEW PAPER
A peer reviewed publication detailing the development of our patented PCR amplification bias control process.
1. Carlson, et al. Nature Communications. 2013.*
2. Data on file with Adaptive Biotechnologies
* Research and/or financial support provided by Adaptive Biotechnologies